1. Home
  2. SOBR vs CDT Comparison

SOBR vs CDT Comparison

Compare SOBR & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOBR Safe Inc.

SOBR

SOBR Safe Inc.

HOLD

Current Price

$2.19

Market Cap

2.4M

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.45

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOBR
CDT
Founded
2004
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOBR
CDT
Price
$2.19
$1.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.2M
388.8K
Earning Date
11-12-2025
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$364,164.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
98.07
N/A
52 Week Low
$1.27
$1.43
52 Week High
$14.50
$2,198.40

Technical Indicators

Market Signals
Indicator
SOBR
CDT
Relative Strength Index (RSI) 58.48 36.47
Support Level $1.29 $1.61
Resistance Level $2.95 $1.75
Average True Range (ATR) 0.20 0.16
MACD 0.10 -0.01
Stochastic Oscillator 53.61 0.55

Price Performance

Historical Comparison
SOBR
CDT

About SOBR SOBR Safe Inc.

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: